Table 4.
Demographic data for subgroups with antibodies to self-antigens data
| Characteristic | Total (n=40) | FN/Col-IV Abs+ (n=16) | FN/Col-IV Abs− (n=24) | P Value |
|---|---|---|---|---|
| Polyomavirus reactivation, n (%) | 31 (78) | 15 (94) | 16 (67) | 0.04 |
| BK viremia, n (%) | 20 (50) | 8 (50) | 12 (50) | |
| JC viruria, n (%) | 11 (28) | 7 (44) | 4 (17) | 0.09 |
| No BK viremia or JC viruria, n (%) | 9 (23) | 1 (6) | 8 (33) | |
| Age, yr | 47±14 | 47±16 | 48±13 | 0.89 |
| Men, n (%) | 25 (63) | 11 (69) | 14 (58) | 0.51 |
| Black race, n (%) | 6 (15) | 1 (6) | 5 (21) | 0.21 |
| Initial calcineurin inhibitor (tacrolimus/cyclosporin) | 28/12 | 10/6 | 18/6 | 0.40 |
| Initial antimetabolite (MMF/azathioprine) | 17/23 | 10/6 | 7/17 | 0.04 |
| Deceased donor, n (%) | 26 (65) | 11 (69) | 15 (63) | 0.69 |
| Total HLA mismatches, n | 2.8±1.7 | 2.6±1.4 | 3.0±1.9 | 0.47 |
| Pretransplant FN/Col-IV Abs+, n (%)a | 11 of 36 (31) | 3 of 16 (19) | 8 of 20 (40) | 0.17 |
Comparison of baseline demographic and clinical data between subjects who developed antibodies to self-antigens FN and Col-IV (FN/Col-IV Abs+) and those remaining FN/Col-IV antibody negative (FN/Col-IV Abs−) during year 1 post-transplant. Polyomavirus reactivation was considered as detection of BK viremia or JC viruria, because they were mutually exclusive events in this subgroup analysis. Normally distributed continuous variables were compared using paired t test and are presented as mean±SD. Categoric variables were compared using Pearson chi-squared test or Fisher exact test where appropriate. Percentages listed for each category are in reference to the total number of cases within each column. Comparison of FN/Col-IV Abs+ status across subgroups with polyomavirus reactivation (15 of 31 [48%]), no reactivation (one of 9 [11%]), native stage 3 CKD (three of 12 [25%]), and healthy controls (none of 12 [0%]) was significant at P<0.01 using Pearson chi-squared test.
Pretransplant samples were available in 36 out of 40 subjects. Of the three subjects who tested positive for antibodies to FN and Col-IV both pre- and post-transplant, all initially tested negative at 1 month post-transplant so we considered all post-transplant antibodies to be de novo events.